Get the Stockscreener App
4.41
0.68%
-0.03
Pre-market:
4.49
0.08
+1.81%
Cytek Biosciences Inc stock is traded at $4.41, with a volume of 795.00K.
It is down -0.68% in the last 24 hours and down -10.55% over the past month.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
See More
Previous Close:
$4.44
Open:
$4.46
24h Volume:
795.00K
Relative Volume:
0.83
Market Cap:
$563.88M
Revenue:
$193.01M
Net Income/Loss:
$-12.15M
P/E Ratio:
-49.00
EPS:
-0.09
Net Cash Flow:
$454.00K
1W Performance:
+0.92%
1M Performance:
-10.55%
6M Performance:
+10.80%
1Y Performance:
+2.32%
1-Day Range:
$4.395
$4.58
1-Week Range:
$4.16
$4.60
52-Week Range:
$2.37
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Name
Cytek Biosciences Inc
Sector
Industry
Phone
(877) 922-9835
Address
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.41 | 567.72M | 193.01M | -12.15M | 454.00K | -0.09 |
|
ABT
Abbott Laboratories
|
113.10 | 197.42B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
381.89 | 147.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
95.60 | 124.16B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.21 | 109.58B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
85.22 | 49.49B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-09-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-31-25 | Downgrade | Goldman | Buy → Sell |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Jul-19-23 | Initiated | Raymond James | Mkt Perform |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
View All
Cytek Biosciences Inc Stock (CTKB) Latest News
CTKB SEC FilingsCytek Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Cytek Biosciences at TD Cowen Health Care: Strategic Growth Insights By Investing.com - Investing.com Canada
CTKB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Webinar explores cell sorting breakthroughs, Cytek Biosciences outlines - Traders Union
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q4 2025 Earnings Call Transcript - Insider Monkey
Cytek Biosciences (NASDAQ:CTKB) Announces Quarterly Earnings Results, Misses Estimates By $0.36 EPS - MarketBeat
Cytek (CTKB) Q4 2025 Earnings Call Transcript - AOL.com
Cytek Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Cytek Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CTKB) 2026-02-27 - Seeking Alpha
Cytek Biosciences (CTKB) Q4 EPS Swing To Loss Reinforces Margin Concerns - Sahm
Cytek Biosciences earnings missed by $0.32, revenue topped estimates - Investing.com Canada
Cytek Biosciences Q4 Earnings Call Highlights - Yahoo Finance
Earnings Call Summary | Cytek Biosciences(CTKB.US) Q4 2025 Earnings Conference - 富途牛牛
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
Earnings call transcript: Cytek Biosciences Q4 2025 sees record revenue, EPS miss - Investing.com Canada
Cytek Biosciences Inc. (CTKB) Stock Falls on Q4 2025 Earnings - Quiver Quantitative
Cytek Biosciences, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
Cytek Biosciences, Inc. (CTKB) Stock Analysis: Exploring a Potential 37% Upside Amid Challenging Valuations - DirectorsTalk Interviews
Aug Chart Watch: Is Cytek Biosciences Inc stock overvalued or fairly priced2025 Pullback Review & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Cytek Biosciences (CTKB) CTO exercises RSUs and surrenders shares for tax - Stock Titan
Cytek Biosciences (CTKB) Expected to Announce Earnings on Thursday - Defense World
Cytek Biosciences to participate at the TD Cowen 46th Annual Health Care Conference - The Manila Times
Live March 4 Cytek Biosciences talk at TD Cowen health care conference - Stock Titan
CTKB Should I Buy - Intellectia AI
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Share Price Is Still Matching Investor Opinion Despite 27% Slump - simplywall.st
Cytek Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - marketscreener.com
Cytek Biosciences, Inc. (CTKB): Investor Outlook On A Promising 37.61% Upside Potential - DirectorsTalk Interviews
Is Cytek Biosciences Inc. in a long term uptrendJuly 2025 Weekly Recap & Long Hold Capital Preservation Plans - mfd.ru
Cytek Biosciences Stock (CTKB) Opinions on Preliminary Q4 and FY2025 Revenue Results - Quiver Quantitative
What are Cytek Biosciences Inc.’s technical support levels2025 Investor Takeaways & Expert Curated Trade Setup Alerts - mfd.ru
Can Cytek Biosciences Inc. stock hit analyst price targets2025 Market WrapUp & Real-Time Buy Signal Alerts - mfd.ru
New York State Common Retirement Fund Has $1.15 Million Holdings in Cytek Biosciences, Inc. $CTKB - MarketBeat
Why Cytek Biosciences Inc. stock is trending among retail tradersPortfolio Update Summary & AI Enhanced Market Trend Forecasts - mfd.ru
What You Can Learn From Cytek Biosciences, Inc.'s (NASDAQ:CTKB) P/S - 富途牛牛
Cytek Biosciences, Inc. (NASDAQ:CTKB) Given Consensus Rating of "Hold" by Analysts - MarketBeat
Brown Capital Management LLC Has $17.20 Million Position in Cytek Biosciences, Inc. $CTKB - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Trading Up 3.2%Should You Buy? - MarketBeat
Cytek Biosciences (NASDAQ:CTKB) Trading Up 3.2% – Should You Buy? - Defense World
Market Outlook: Does Cytek Biosciences Inc stock benefit from AI growthEarnings Recap Report & Technical Buy Zone Confirmations - baoquankhu1.vn
This Cytek Biosciences Insider Increased Their Holding By 169% Last Year - Yahoo Finance
Cytek Biosciences, Inc. (CTKB) Investor Outlook: Navigating the Healthcare Sector with a 17% Potential Upside - DirectorsTalk Interviews
Cytek Biosciences Data Breach Investigation - Strauss Borrelli PLLC
Aug Closing: Is Cytek Biosciences Inc stock overvalued or fairly priced2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Cytek Biosciences, Inc. (CTKB) Investor Outlook: Analyzing The 8.70% Potential Upside - DirectorsTalk Interviews
Institutional owners may take dramatic actions as Cytek Biosciences, Inc.'s (NASDAQ:CTKB) recent 6.9% drop adds to one-year losses - simplywall.st
Why Cytek Biosciences Inc. (8EQ) stock attracts HNW investorsJuly 2025 Big Picture & High Conviction Investment Ideas - bollywoodhelpline.com
CYTEK BIOSCIENCES Q4 2025 Earnings Preview: Recent $CTKB Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Cytek Biosciences (NASDAQ:CTKB) Shares Up 8.2%Here's What Happened - MarketBeat
Cytek Biosciences, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 - marketscreener.com
Cytek Biosciences, Inc. (NASDAQ:CTKB) Receives Average Rating of “Hold” from Analysts - Defense World
Cytek Biosciences Inc Stock (CTKB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.27%
1.94%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):